Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

NCT02118415 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IIIA/B

Interventions

OTHER: Hsp70-peptide TKD/IL-2 activated, autologous NK cells

Sponsor

Technical University of Munich